837P Phase II trial of oncolytic vaccinia virus primed immunochemotherapy in platinum-resistant/refractory ovarian cancer (PRROC) (NCT02759588)
Holloway, R.W., Mendivil, A.A., Kendrick, J.E., Abaid, L.N., Brown, J.V., Fitzsimmons, C.K., Kennard, J.A., King, M., LeBlanc, J., Lopez, K., Manyam, M., McKenzie, N.D., Mori, K.M., Stephens, A.J., Ahmad, S.
Published in Annals of oncology (01.09.2020)
Published in Annals of oncology (01.09.2020)
Get full text
Journal Article
Phase II VIRO-15 trial of olvimulogene nanivacirepvec (Olvi-Vec)-primed immunochemotherapy in platinum-resistant/refractory ovarian cancer (PRROC) (NCT02759588)
Holloway, R.W., Mendivil, A.A., Kendrick, J.E., Abaid, L.N., Brown, J.V., Fitzsimmons, C.K., Kennard, J.A., King, M.M., LeBlanc, J., Lopez, K., Manyam, M., McKenzie, N.D., Mori, K.M., Smith, J.L., Stephens, A.J., Ahmad, S.
Published in Gynecologic oncology (01.10.2020)
Published in Gynecologic oncology (01.10.2020)
Get full text
Journal Article